Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive‐resistant differentiated thyroid cancer

This review focuses on patients with differentiated thyroid carcinoma (DTC) associated with multiple primary malignant neoplasm (MPMN) treated by multikinase inhibitors (MKIs) as systemic treatment for advanced disease. Despite the increasing frequency of MPMNs (many at an advanced stage) and the us...

Descripción completa

Detalles Bibliográficos
Autor principal: Sambo, Marcel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537058/
https://www.ncbi.nlm.nih.gov/pubmed/36202607
http://dx.doi.org/10.1002/cam4.5107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537058/
https://www.ncbi.nlm.nih.gov/pubmed/36202607
http://dx.doi.org/10.1002/cam4.5107

Ejemplares similares